An FDA Advisory panel just gave a positive recommendation on Novartis' CAR T treatment for cancer. Novartis reports that 75% of terminally ill cancer patients that received treatment are cancer free.
This is the most exciting advancement in medicine of our lifetimes.
The big challenge will be price point. CAR T treatment is personalized medicine and so it's very expensive.
Novartis chart does not look like a good setup right now IMO. I'd like to see more consolidation and evidence large players are buying before taking an entry.
This is the most exciting advancement in medicine of our lifetimes.
The big challenge will be price point. CAR T treatment is personalized medicine and so it's very expensive.
Novartis chart does not look like a good setup right now IMO. I'd like to see more consolidation and evidence large players are buying before taking an entry.